Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
